Maxime Faure

Immune checkpoint inhibitor-associated myocarditis: a novel risk score

John R. Power, Charles Dolladille, Benay Özbay, Adrien Procureur et autres

BACKGROUND AND AIMS: Immune checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI myocarditis can manifest concurrent generalized myositis, myasthenia-like syndrome, and respiratory muscle failure. Prognostic factors for this 'cardiomyotoxicity' …

us, fr, de, il, jp, at, au, gb, es, ch, tw (code pays fourni par la source)

Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor

Anne‐Claire Toublanc, Maxime Faure, Guillaume Verdy, Audrey Rabeau et autres

fr (code pays fourni par la source)

Right Ventriculoarterial Coupling Surrogates and Long-Term Survival in LVAD Recipients: Results of the ASSIST-ICD Multicentric Registry

Maxime Beneyto, Raphaël P. Martins, Vincent Galand, Michel Kindo et autres

BACKGROUND: Prediction of outcomes remains an unmet need in candidates for LVADs. The development of right-heart failure portends an excess in mortality rates, but imaging parameters of right ventricular systolic function have failed to demonstrate a prognostic role. By integrating pulmonary pressure, …

fr (code pays fourni par la source)

Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study

Marin Lahouati, Aur lie Labadie, Philippe Gohier, Laura Guirle et autres

The aim of this study was to describe the outcomes of targeted COVID-19 treatments in immunocompromised patients with asymptomatic or mild COVID-19 during the period of expansion of the different Omicron subvariants in France. A retrospective monocentric observational study was performed. All …

fr (code pays fourni par la source)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series

Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, C. Lesage et autres

BACKGROUND: Immune checkpoint inhibitors (ICI) have transformed cancer treatment over the last decade. Alongside this therapeutic improvement, a new variety of side effects has emerged, called immune-related adverse events (irAEs), potentially affecting any organ. Among these irAEs, myocarditis is rare but life-threatening. …

fr (code pays fourni par la source)

A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer

Clara Faubry, Maxime Faure, Anne‐Claire Toublanc, Rémi Veillon et autres

Background: Immune checkpoint inhibitors (ICIs) are widely used in lung cancer management. However, myocarditis, which is a rare, yet potentially severe adverse-related event associated with ICIs, could be under-reported. Objectives: This study is aimed to prospectively evaluate the cumulative incidence rate of …

fr (code pays fourni par la source)

Facteurs pronostiques des myocardites induites par les inhibiteurs du checkpoint immunologique

Cyrille Coustal, Xavier Quantin, C. Lesage, Jean‐Marie Michot et autres

fr, in (code pays fourni par la source)

Les brûlures liées aux dispositifs médicaux du point de vue de la matériovigilance

B. Saleh-Jawiche, Carles Quiñones Ribas, Maxime Faure, Élodie Fache et autres

fr (code pays fourni par la source)

272 Discovery and Development of Potent CDK9-selective Inhibitors for Cancer Treatment

Zhenhai Gao, James Sutton, Thomas A. Abrams, Maxime Faure et autres